source
- Cardiac biotech Braveheart raises $382.5M in IPO, launches on Nasdaq as BRVEBraveheart Bio, a cardiac drug developer, priced its initial public offering on Wednesday and secured $382.5 million in proceeds. The company sold about 21.2 million shares at $18 each, exceeding t…
- Sarepta delays Elevidys study readout while Emergent cuts 90 jobsSarepta Therapeutics told investors that the readout for its non‑ambulatory Elevidys trial will not be available by the end of the year as previously expected. The company indicated the delay durin…